# Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

> **NCT03768531** · PHASE2 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Resectable Biliary Tract Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Cabrilizumab

## Key facts

- **NCT ID:** NCT03768531
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-14
- **Primary completion:** 2023-01
- **Final completion:** 2023-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects were enrolled
- **Last updated:** 2020-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03768531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03768531, "Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03768531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*